This article was originally published in The Gray Sheet
Second tranche of a $15 mil. private placement is complete. The sale of approximately 1.7 mil. shares at $2 each follows the Jan. 21 placement of about 5.8 mil. shares at the same price. The proceeds, in conjunction with a 30% company-wide reduction in workforce, will facilitate the continuing European roll-out of the Revelation and Revelation Tx microcatheters for therapeutic treatment of atrial fibrillation. An ongoing U.S. AF trial also will be expanded
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.